Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency.
Use of recombinant factor VIIa (rFVIIa, NovoSeven in patients with congenital FVII deficiency has been reported for the prophylactic management of surgical bleeding and for the treatment of acute bleeding episodes. Because of its short half-life, the use of rFVIIa on a regular prophylactic regimen has not been routinely adopted. In this report, we describe our successful experience with rFVIIa prophylaxis in preventing recurrent target joint bleeding in a severely FVII-deficient adolescent.
Tcheng
W Y
WY
Childrens Hospital Los Angeles, Department of Hematology-Oncology, Los Angeles, CA, USA.
Donkin
J
J
Konzal
S
S
Wong
W-Y
WY
D000293:Adolescent; D005167:Factor VII / Q000627:therapeutic use*; D005168:Factor VII Deficiency / Q000151:congenital / Q000517:prevention & control*; D015942:Factor VIIa; D006395:Hemarthrosis / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use*
D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa